JP2011515472A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515472A5 JP2011515472A5 JP2011501846A JP2011501846A JP2011515472A5 JP 2011515472 A5 JP2011515472 A5 JP 2011515472A5 JP 2011501846 A JP2011501846 A JP 2011501846A JP 2011501846 A JP2011501846 A JP 2011501846A JP 2011515472 A5 JP2011515472 A5 JP 2011515472A5
- Authority
- JP
- Japan
- Prior art keywords
- patent document
- bendamustine hydrochloride
- ribosepharm
- discloses
- bendamustine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 3
- 229960001215 bendamustine hydrochloride Drugs 0.000 description 3
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- TWBJYCLUHINEDN-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydrate;hydrochloride Chemical compound O.Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 TWBJYCLUHINEDN-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3975208P | 2008-03-26 | 2008-03-26 | |
| US61/039,752 | 2008-03-26 | ||
| PCT/US2009/001956 WO2009120386A2 (en) | 2008-03-26 | 2009-03-26 | Novel solid forms of bendamustine hydrochloride |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011515472A JP2011515472A (ja) | 2011-05-19 |
| JP2011515472A5 true JP2011515472A5 (https=) | 2013-05-23 |
| JP5536753B2 JP5536753B2 (ja) | 2014-07-02 |
Family
ID=41051023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011501846A Active JP5536753B2 (ja) | 2008-03-26 | 2009-03-26 | ベンダムスチン塩酸塩の新規固体形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (9) | US20090264488A1 (https=) |
| EP (2) | EP2271315B1 (https=) |
| JP (1) | JP5536753B2 (https=) |
| CN (3) | CN105693620A (https=) |
| AR (1) | AR072777A1 (https=) |
| CA (1) | CA2718939A1 (https=) |
| CL (1) | CL2009000742A1 (https=) |
| ES (1) | ES2605205T3 (https=) |
| HK (1) | HK1220966A1 (https=) |
| MX (2) | MX339878B (https=) |
| TW (1) | TWI472515B (https=) |
| WO (1) | WO2009120386A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| EP2219605B1 (en) * | 2007-10-09 | 2015-08-19 | US Worldmeds LLC | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| EP2326306A1 (en) * | 2008-09-25 | 2011-06-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| UA107186C2 (xx) * | 2008-12-03 | 2014-12-10 | Тверді форми дозування бендамустину | |
| WO2010144675A1 (en) * | 2009-06-10 | 2010-12-16 | Plus Chemicals Sa | Polymorphs of bendamustine hcl and processes for preparation thereof |
| EP2516404A4 (en) | 2009-12-23 | 2013-04-17 | Reddys Lab Ltd Dr | PREPARATION OF BENDAMUSTINE AND ITS SALTS |
| PL3158991T3 (pl) | 2010-01-28 | 2021-09-27 | Eagle Pharmaceuticals, Inc. | Preparaty bendamustyny |
| US20130202693A1 (en) | 2010-06-02 | 2013-08-08 | Astellas Deutschland Gmbh | Oral Dosage Forms of Bendamustine |
| JO3659B1 (ar) | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| CN101948437B (zh) * | 2010-06-28 | 2012-08-29 | 江苏奥赛康药业股份有限公司 | 一种盐酸苯达莫司汀的精制方法 |
| US20130217888A1 (en) | 2010-11-01 | 2013-08-22 | Shailpa Medicare Limited | Process for preparing bendamus tine hydrochloride monohydrate |
| WO2012103226A2 (en) * | 2011-01-25 | 2012-08-02 | Dr. Reddy's Laboratories Ltd. | Bendamustine formulations |
| WO2012106117A1 (en) * | 2011-01-31 | 2012-08-09 | Cephalon, Inc. | Methods for the preparation of bendamustine |
| EP2760842B1 (en) | 2011-09-26 | 2016-11-16 | Fresenius Kabi Oncology Ltd | An improved process for the preparation of bendamustine hydrochloride |
| CN102351799B (zh) * | 2011-10-24 | 2014-02-26 | 江苏奥赛康药业股份有限公司 | 一种盐酸苯达莫司汀晶型及其制备方法 |
| EP2617716A1 (en) | 2012-01-18 | 2013-07-24 | Arevipharma GmbH | Process for the preparation of bendamustine hydrochloride and related compounds |
| CA2867295C (en) | 2012-03-20 | 2020-08-11 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| PL2827863T3 (pl) | 2012-03-20 | 2019-07-31 | Eagle Pharmaceuticals, Inc. | Ciekła kompozycja do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania |
| US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| WO2013150020A1 (en) | 2012-04-03 | 2013-10-10 | Synthon Bv | Process for making bendamustine |
| PT2656843E (pt) | 2012-04-26 | 2015-04-14 | Helmut Schickaneder | Ésteres de bendamustina e compostos relacionados e a sua utilização médica |
| US9801859B2 (en) * | 2012-09-18 | 2017-10-31 | Innopharma Licensing, Llc | Bendamustine formulations |
| BR112015010501A2 (pt) | 2012-11-12 | 2017-07-11 | Ignyta Inc | composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada |
| EP2958554B1 (en) | 2013-02-19 | 2018-06-06 | Synthon BV | Stable compositions of bendamustine |
| US9315469B2 (en) | 2013-03-14 | 2016-04-19 | Johnson Matthey Public Limited Company | Process for drying bendamustine hydrochloride monohydrate |
| WO2014170769A2 (en) * | 2013-04-15 | 2014-10-23 | Shilpa Medicare Limited | Bendamustine lyophilized pharmaceutical compositions |
| ES2957541T3 (es) | 2013-08-27 | 2024-01-22 | Vasilios Voudouris | Composiciones farmacéuticas de bendamustina |
| CA2941632C (en) | 2014-03-13 | 2023-10-24 | Vasilios VOUDOURIS | Bendamustine solid dispersions and continuous infusion |
| EP2985038A1 (en) | 2014-08-12 | 2016-02-17 | Azad Pharma AG | Lyophilized API preparation |
| US10342769B2 (en) | 2014-11-14 | 2019-07-09 | Navinta Iii Inc | Carmustine pharmaceutical composition |
| US9603930B2 (en) | 2014-12-04 | 2017-03-28 | Navinta, Llc | Liquid bendamustine formulation |
| CN107921072A (zh) * | 2015-06-09 | 2018-04-17 | 雷柏奥提斯有限公司 | 微生物群恢复治疗（mrt）组合物和制造方法 |
| US10905677B2 (en) | 2016-08-31 | 2021-02-02 | Navinta, Llc | Bendamustine solution formulations |
| US11826466B2 (en) | 2016-08-31 | 2023-11-28 | Navinta, Llc | Bendamustine solution formulations |
| SG11202003098WA (en) | 2017-10-05 | 2020-05-28 | Tube Pharmaceuticals Gmbh | Oral bendamustine formulations |
| WO2019091373A1 (zh) * | 2017-11-07 | 2019-05-16 | 江苏恒瑞医药股份有限公司 | 一种盐酸苯达莫司汀的晶体及其制备方法 |
| EA037673B1 (ru) * | 2018-07-04 | 2021-04-29 | Тютор С.А.С.И.Ф.И.А. | Способ получения фармацевтической композиции, содержащей бендамустин, фармацевтическая композиция бендамустина |
| ES3055021T3 (en) | 2018-08-17 | 2026-02-09 | Hospira Australia Pty Ltd | Liquid bendamustine pharmaceutical compositions |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022103638A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| JP2024537431A (ja) | 2021-10-22 | 2024-10-10 | プロジェクト ファーマシューティクス ゲーエムベーハー | 液状薬学的製剤 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE159877C (https=) * | ||||
| DE159289C (https=) | 1903-10-08 | 1905-03-16 | ||
| DD80967A (https=) | ||||
| DE80967C (https=) | ||||
| DE293808C (https=) | ||||
| DE34727C (de) | Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue | Verfahren zur direkten Gewinnung metallischen Bleis | ||
| DD34727A1 (de) | 1963-12-21 | 1964-12-28 | Dietrich Krebs | Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren |
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| US4012448A (en) | 1976-01-15 | 1977-03-15 | Stanford Research Institute | Synthesis of adriamycin and 7,9-epiadriamycin |
| DD159289A1 (de) | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| DD159877A1 (de) * | 1981-06-12 | 1983-04-13 | Wolfgang Krueger | Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure |
| IT1153974B (it) | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
| US4537883A (en) | 1982-11-12 | 1985-08-27 | Mead Johnson & Company | Lyophilized cyclophosphamide |
| US5227374A (en) | 1982-11-12 | 1993-07-13 | Mead Johnson & Company | Lyophilized cyclophosphamide |
| US4659699A (en) | 1983-08-22 | 1987-04-21 | Cetus-Ben Venue Therapeutics | Process for freeze drying cyclophosphamide |
| US5183746A (en) | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
| US5204335A (en) * | 1986-10-31 | 1993-04-20 | Asta Pharma Aktiengesellschaft | Ifosfamide lyophilisate and process for its preparation |
| US4879286A (en) | 1987-01-28 | 1989-11-07 | Lyphomed, Inc. | Cyclophosphamide |
| EP0334083B1 (de) | 1988-03-19 | 1991-07-24 | ASTA Pharma Aktiengesellschaft | Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung |
| DE3907079A1 (de) | 1988-03-19 | 1989-09-28 | Asta Pharma Ag | Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung |
| US5036060A (en) | 1988-07-25 | 1991-07-30 | Fujisawa Usa, Inc. | Cyclophosphamide |
| CA2001552C (en) | 1988-11-14 | 1997-07-22 | The Upjohn Company | Cyclophosphamide - sodium bicarbonate lyophilizates |
| US5066647A (en) | 1989-04-20 | 1991-11-19 | Erbamont, Inc. | Cyclophosphamide - alanine lyophilizates |
| US5051257A (en) | 1989-05-09 | 1991-09-24 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
| DD293808A5 (de) | 1990-04-23 | 1991-09-12 | Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De | Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern |
| US5268368A (en) | 1991-05-17 | 1993-12-07 | Erbamont, Inc. | Cyclophosphamide--amino acid lyophilizates |
| US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
| US5192743A (en) | 1992-01-16 | 1993-03-09 | Genentech, Inc. | Reconstitutable lyophilized protein formulation |
| MD1367C2 (ro) * | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5418223A (en) | 1993-05-20 | 1995-05-23 | Erbamont, Inc. | Method for lyophilization of cyclophosphamide and product |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US5741523A (en) * | 1993-10-27 | 1998-04-21 | Pharmacia & Upjohn Company | Stabilized prostaglandin E1 |
| US5561121A (en) | 1993-11-09 | 1996-10-01 | American Cyanamid Company | Stable lyophilized thiotepa composition |
| US5955504A (en) | 1995-03-13 | 1999-09-21 | Loma Linda University Medical Center | Colorectal chemoprotective composition and method of preventing colorectal cancer |
| DE19529057B4 (de) * | 1995-08-08 | 2007-12-13 | Baxter Healthcare S.A. | Ifosfamid-Lyophilisat-Zubereitungen |
| JPH11511463A (ja) | 1995-08-31 | 1999-10-05 | スミスクライン・ビーチャム・コーポレイション | インターロイキン変換酵素およびアポプトーシス |
| DE69624081T2 (de) | 1995-12-20 | 2003-06-12 | Agouron Pharmaceuticals, Inc. | Matrix-metalloprotease Inhibitoren |
| US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
| US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
| US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| US20040072889A1 (en) * | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
| CA2294247C (en) | 1997-07-01 | 2004-10-26 | Atherogenics, Inc. | Antioxidant enhancement of therapy for hyperproliferative conditions |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| DE69929440T2 (de) * | 1998-07-09 | 2006-08-17 | Cephalon, Inc. | Zusammensetzungen zur behandlung chronischer lymphatischer leukämie |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US5972912A (en) * | 1998-12-17 | 1999-10-26 | S.P. Pharmaceuticals | Method for lyophilizing ifosfamide |
| US6569402B1 (en) * | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| US6380210B1 (en) * | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
| US6545034B1 (en) * | 1999-07-23 | 2003-04-08 | The Regents Of The University Of California | Use of etodolac for the treatment of chronic lymphocytic leukemia |
| DE10016077A1 (de) | 2000-03-31 | 2001-12-13 | Cellcontrol Biomedical Lab Gmb | Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen |
| AUPQ849900A0 (en) | 2000-06-30 | 2000-07-27 | Dbl Australia Pty Ltd. | Injectable composition |
| US20040152672A1 (en) * | 2000-08-09 | 2004-08-05 | Carson Dennis A. | Indole compounds useful for the treatment of cancer |
| CA2431319A1 (en) * | 2000-12-11 | 2002-06-20 | Hiroto Bando | Pharmaceutical composition having an improved water solubility |
| WO2002048142A1 (en) * | 2000-12-11 | 2002-06-20 | Takeda Chemical Industries, Ltd. | Medicinal compositions having improved absorbability |
| WO2002080996A1 (de) * | 2001-04-03 | 2002-10-17 | Franz Herbst | Medizinisches implantat und verfahren zu seiner herstellung |
| KR100679990B1 (ko) * | 2001-10-15 | 2007-02-08 | 헤모텍 게엠베하 | 재협착증의 방지를 위한 스텐트의 코팅 |
| US6613927B1 (en) * | 2002-02-08 | 2003-09-02 | American Pharmaceutical Partners, Inc. | Sterile lyophilized ifosfamide and associated methods |
| DE10306724A1 (de) | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Vesikuläre Verkapselung von Bendamustin |
| US6780324B2 (en) | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
| EP1485720B1 (en) | 2002-03-22 | 2008-03-12 | Ludwig Maximilians Universität | Cytocapacity test |
| EP1495124A2 (en) | 2002-04-17 | 2005-01-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| EP1354952A1 (en) | 2002-04-17 | 2003-10-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| DE10393059D2 (de) * | 2002-05-09 | 2005-05-04 | Hemoteq Gmbh | Verbindungen und Verfahren zur hemokompatiblen Beschichtung von Oberflächen |
| AU2003258061A1 (en) * | 2002-08-02 | 2004-02-23 | Salmedix, Inc. | Therapeutic inhibitionof protein kinases in cancer cells |
| NZ540318A (en) | 2002-10-31 | 2007-09-28 | Umd Inc | Therapeutic compositions for drug delivery to and through covering epithelia |
| DE10304403A1 (de) | 2003-01-28 | 2004-08-05 | Röhm GmbH & Co. KG | Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung |
| EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| CA2516191A1 (en) * | 2003-02-14 | 2004-09-02 | Salmedix, Inc | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers |
| CN1829514A (zh) * | 2003-07-25 | 2006-09-06 | 惠氏公司 | Cci－779冻干制剂 |
| JP2008519047A (ja) | 2004-11-05 | 2008-06-05 | セフアロン・インコーポレーテツド | 癌処置 |
| ATE476962T1 (de) | 2004-11-22 | 2010-08-15 | Venus Remedies Ltd | Nichtwässrige flüssige parenterale aceclofenac- formulierung |
| EP1674081A1 (de) * | 2004-12-23 | 2006-06-28 | KTB Tumorforschungsgesellschaft mbH | Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge |
| UA94036C2 (ru) * | 2005-01-14 | 2011-04-11 | Сефалон, Инк. | Фармацевтическая композиция бендамустина, предназначенная для лиофилизации |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| US7872050B2 (en) | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
| ES2365410T3 (es) | 2005-04-08 | 2011-10-04 | Amylin Pharmaceuticals, Inc. | Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico. |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| ITUD20070130A1 (it) | 2007-07-23 | 2009-01-24 | C M E Spa Sa | Macchina e procedimento per la produzione di elementi strutturali per l'edilizia in materiale cementizio aventi uno o piu' inserti in materiale polimerico |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| EP2326306A1 (en) | 2008-09-25 | 2011-06-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| MX2011011109A (es) | 2009-04-28 | 2011-11-18 | Cephalon Inc | Formulaciones orales de bendamustina. |
-
2009
- 2009-03-23 AR ARP090101039A patent/AR072777A1/es not_active Application Discontinuation
- 2009-03-26 CN CN201610027378.XA patent/CN105693620A/zh active Pending
- 2009-03-26 ES ES09723661.6T patent/ES2605205T3/es active Active
- 2009-03-26 WO PCT/US2009/001956 patent/WO2009120386A2/en not_active Ceased
- 2009-03-26 CN CN2009801107677A patent/CN101980698B/zh active Active
- 2009-03-26 TW TW098110003A patent/TWI472515B/zh active
- 2009-03-26 CN CN201310415249.4A patent/CN103550159B/zh active Active
- 2009-03-26 US US12/411,929 patent/US20090264488A1/en not_active Abandoned
- 2009-03-26 EP EP09723661.6A patent/EP2271315B1/en active Active
- 2009-03-26 CL CL2009000742A patent/CL2009000742A1/es unknown
- 2009-03-26 MX MX2013011045A patent/MX339878B/es unknown
- 2009-03-26 EP EP16188467.1A patent/EP3150197A1/en not_active Withdrawn
- 2009-03-26 JP JP2011501846A patent/JP5536753B2/ja active Active
- 2009-03-26 MX MX2010010398A patent/MX2010010398A/es active IP Right Grant
- 2009-03-26 CA CA2718939A patent/CA2718939A1/en not_active Abandoned
-
2011
- 2011-11-22 US US13/301,979 patent/US8445524B2/en active Active
-
2013
- 2013-05-01 US US13/874,575 patent/US8669279B2/en active Active
-
2014
- 2014-03-07 US US14/200,738 patent/US8883836B2/en active Active
- 2014-11-03 US US14/531,023 patent/US20150051258A1/en not_active Abandoned
-
2016
- 2016-02-17 US US15/045,523 patent/US9533955B2/en active Active
- 2016-07-26 HK HK16108932.6A patent/HK1220966A1/zh unknown
- 2016-11-23 US US15/359,777 patent/US10039750B2/en active Active
-
2018
- 2018-07-17 US US16/037,560 patent/US10517852B2/en active Active
-
2019
- 2019-11-18 US US16/686,751 patent/US20200323824A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011515472A5 (https=) | ||
| JP2013537891A5 (https=) | ||
| JP2008523153A5 (https=) | ||
| EA201170272A1 (ru) | Фармацевтическая композиция | |
| JP2014532727A5 (https=) | ||
| CN113412260A (zh) | 己酮糖激酶抑制剂及其用途 | |
| JP2013542247A5 (https=) | ||
| AR067639A1 (es) | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente | |
| JP2011116755A5 (https=) | ||
| FI3300743T3 (fi) | Menetelmiä rokotteen antamiseksi | |
| HRP20221355T1 (hr) | Liofilizirani pripravak citotoksičnih dipeptida | |
| JP2018531987A5 (https=) | ||
| JP2014515747A5 (https=) | ||
| US20240398764A1 (en) | Methods of treating diseases associated with senescent cell accumulation | |
| JP2018529717A5 (https=) | ||
| Al-Karmalawy et al. | Design and statistical optimisation of emulsomal nanoparticles for improved anti-SARS-CoV-2 activity of N-(5-nitrothiazol-2-yl)-carboxamido candidates: in vitro and in silico studies | |
| JP2012504616A5 (https=) | ||
| BR112012013199A2 (pt) | composto, composição farmacêutica, e , uso de um composto | |
| MX2011011526A (es) | Formulacion lipida de promotor de apoptosis. | |
| JP2013532664A5 (https=) | ||
| EP4167984A1 (en) | Anti-viral compounds and methods of using same | |
| WO2009084036A3 (en) | Composition for treatment of viral infections | |
| FR3056108A1 (fr) | Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif | |
| BR112012015170A8 (pt) | Derivado de amino-heteroarila, composição farmacêutica, uso de um derivado de amino-heteroarila, e, método para tratamento de dor | |
| UA109544C2 (uk) | Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення |